



NHS MEDICAL POLICY

Infantile Hemangiomas Procedure 2015-004

A. Treatment of infantile hemangiomas may be indicated when ONE of the following is present:

| | |
|---|--|
| 1 | The member has Kasabach-Merritt Syndrome. (This is a life-threatening complication occurring with kaposiform hemangioendothelioma (KHE) or tufted angioma. It is characterized by profound thrombocytopenia and consumption coagulopathy.) |
| 2 | There is documented functional impairment due to the hemangioma. |
| 3 | There is documented compromise of vital structures due to the hemangioma. |
| 4 | The hemangioma is symptomatic. |

B. Treatment of infantile hemangiomas may be done with any of the following techniques, either alone or in combination:

| | |
|---|-------------------------|
| 1 | Sclerosing therapy |
| 2 | Laser therapy |
| 3 | Cryosurgery/Cryotherapy |
| 4 | Embolization |
| 5 | Radiotherapy |
| 6 | Surgical excision |
| 7 | Intralesional steroids |
| 8 | Oral propranolol |

SOURCES

1. UpToDate.com was accessed Jan 8, 2015.
2. Leaute-Labreze C et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358 (24): 2649-2651.
3. Nguyen J, Fay A. Pharmacologic therapy for periocular infantile hemangiomas: A review of the literature. Semin Ophthalmol. 2009;24(3):178-184.
4. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pediatrics. 2013;131(1):128-140.

CODE REFERENCE (This may not be a comprehensive list of codes to apply to this policy.)

11400-11446, 17106, 17107, 17108, 17110, 17111, 11900, 11901, 77401, 77402, 77403, 77404, 77406

POLICY HISTORY/REVISION INFORMATION

| Date | Action/Description |
|------------|---|
| 03/20/2015 | Approved in UM committee |
| 12/16/2015 | Annual review and approval by UM Committee |
| 12/14/2016 | Annual review and approval by UM Committee |
| 12/13/2017 | Annual review and approval by UM Committee |
| 12/13/2018 | Annual review and approval by UM Committee |
| 12/12/2019 | Annual review and approval by UM Committee |
| 12/10/2020 | Annual review and approval by UM Committee |
| 12/10/2021 | Annual review and approval by UM Committee |
| 12/21/2022 | Annual review and approval by UM Committee |
| 12/20/2023 | Annual review and approval by UM/QM Committee |